# Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone

> **NCT06388616** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 30 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Balcinrenone

## Key facts

- **NCT ID:** NCT06388616
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-02
- **Primary completion:** 2024-09-05
- **Final completion:** 2024-09-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06388616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06388616, "Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06388616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*